Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - September 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of September 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2012-00664 Documents relating to comments or complaints from citizens about health effects from electromagnetic/radio frequencies related to wireless or mobile technology. (Jan 1, 2009 to Jun 30, 2012). Disclosed in part 449
A-2012-00690 Documents relating to voluntary guidelines on nutrition labelling in Canada. (Jul 1, 2011 to Aug 8, 2012). Disclosed in part 404
A-2012-01708 Adverse Reaction Report (AER) for FINASTERIDE. Report numbers: 000376842, 000376884, 000376891, 000376897, 000376898, 000376899, 000376901, 000382698, 000380411, 000380404, 000380403, 000379119, 000371557, 000343895, 000362395. Disclosed in part 38
A-2013-00093 Clinical review reports for Octagam 10%. Disclosed in part 68
A-2013-00300 Labelling documents regarding JAMP-VITAMIN D, Drug Identification Number (DIN) 02379007. Disclosed in part 63
A-2013-00691 Copies of requests for clarification (including responses) received by email in fiscal year 2012-2013 by the Marketed Health Product Directorate. Disclosed in part 139
A-2013-00772 Print Screen Display of all pages contained in documents classified under the Functional Classification System, for Administrative Functions related to Information Technology and Telecommunications: Operations; Safety; Database Management; and Operational functions related to Emergency Preparedness and Response:- Emergency events; Implementation; Reserve Disclosed in part 187
A-2013-00915 The number of births and still born of children with upper limb deficiencies attributed to the use of the drug thalidomide. (1964-1965, Alberta and Nova Scotia). All disclosed 8
A-2013-00964 Documents for the approval of NatureSeal, a preservative used by manufacturers, regarding that only calcium ascorbate is on the label of fresh cut apple slices. Disclosed in part 11
A-2013-01095 Documents related to chiropractor/physiotherapy that is directly or indirectly related to the Non-Insured Health Benefits Program: the number of key policies that have impacted the program benefit list, key impacting policy changes impacting the benefit list, Payer of Last Resort Policy. (Jan 1, 1979 to Dec 10, 2013). Disclosed in part 117
A-2013-01474 Letter issued prior to November 9, 2012 from Therapeutic Products Directorate to Ranbaxy Pharmaceuticals Canada Inc certifying that the examination of RAN-Sildenafil (Sildenafil) was complete. Disclosed in part 2
A-2014-00040 Information regarding Oscillococcinum; Oscillo, Homeopathic Medicine Number (DIN-HM) 80014156 by Boiron Canada Inc. (Jan 1, 2007 to Apr 11, 2014). Disclosed in part 179
A-2014-00041 Information regarding Cough And Cold Kids 0-9, Homeopathic Medicine Number (DIN-HM) 80022446 by Homeocan Inc. (Jan 1, 2009 to Apr 11, 2014). Disclosed in part 104
A-2014-00109 Adverse Reaction Report (AER) for PANTOLOC. Report numbers: 000490247, 000491996, 000497226, 000511807, 000522269, 000525913, 000527250, 0000531666, 000564419, 000572316, 000574464. Disclosed in part 23
A-2014-00142 All call-ups under the terms of the ANY Standing Offer or Supply Arrangement for Temporary Help Services issued in the cities of Calgary, Vancouver and Toronto. (Jan 1, 2013 to Mar 31, 2014). Disclosed in part 160
A-2014-00176 Communications with Greenleaf Medicinals. (Mar. 1, 2014 to May 5, 2014). Disclosed in part 160
A-2014-00197 Adverse Reaction Report (AER) for Fludara. Report number: E2B_00035315. Disclosed in part 16
A-2014-00201 Adverse Reaction Report (AER) for Plavix. Report number: 000565566. Disclosed in part 6
A-2014-00239 Qualifying Notice for the following products: Velcade (Bortezomib), Sprycel (Dasatinib), Isentress (Raltegravir), Tasigna (Nilotinib). Disclosed in part 10
A-2014-00245 Adverse Reaction Report (AER) for Synthroid. Report numbers: 000570482, 000571281, 000575933, 000578499, 000579078. Disclosed in part 23
A-2014-00267 Documents regarding the role of physicians in the new medical marihuana regime taking effect April 1, 2014. (Jan. 1, 2011 to Feb 26, 2014). Disclosed in part 583
A-2014-00352 All information concerning the recall of Watkins All-Purpose Cleaner Concentrate and Liquid Dish Soap Concentrate. Identification number RA-500001722. Disclosed in part 33
A-2014-00359 Documents regarding how tobacco products manufacturers reports on smoke emission testing are processed. (Jan 1, 2006 to Jan 31, 2013). Disclosed in part 198
A-2014-00367 Briefing notes prepared for the Minster and/or the Minister's office dealing with electronic cigarettes. (Nov 1, 2013 to Jun 1, 2014). Disclosed in part 13
A-2014-00394 Correspondence with representatives of the Campaign for Tobacco Free Kids. (Jan 1, 2012 to Jun 26, 2014). Disclosed in part 59
A-2014-00400 Documents pursuant to the Marihuana for Medical Purposes Regulations (MMPR) for licensed producers (Jan 1, 2014 to Jun 30, 2014): Policies or procedures for processing applications; Advertising restrictions; Delays in processing applications; Timing of granting licences or the maximum or anticipated number of licences; Inspection policies or procedures; Processing of security clearance applications; Refusal of applications Disclosed in part 73
A-2014-00430 Adverse Reaction Report (AER). Report number: E2B_00041432. Disclosed in part 11
A-2014-00491 Full amount spent on French Language Training for the Director General of the Natural Health Products Directorate and the Market Health Products Directorate. Disclosed in part 82
A-2014-00525 Drinking Water Advisories issued in First Nations communities across Canada. (Jan 1, 2011 to Jul 25, 2014). All disclosed 48
A-2014-00553 Documents related to the guideline Safety Code 6, Limits of Human Exposure to Radiofrequency Electromagnetic Energy in the Frequency Range from 3 kHz to 300 GHz. (Jun 15, 2014 to Jul 31, 2014). Disclosed in part 215
A-2014-00560 Documents related to marihuana for medical purposes: Case management plan for triaging applications, guidelines and procedures, criteria currently used to determine rank order in priorities for processing applicants. All exempted 0
A-2014-00575 Documents pertaining to the Procurement Strategy for Aboriginal Business, Target & Spend and Performance Reports for calendar year 2012 and 2013. All disclosed 4
A-2014-00578 Information regarding DEBILINE, Drug Identification Number (DIN) 00145491 by LAB NADEAU LT╔E, DIVISION OF TECHNILAB INC. Disclosed in part 1
A-2014-00579 Information regarding DEBILINE H, Drug Identification Number (DIN) 00145653 by LAB NADEAU LT╔E, DIVISION OF TECHNILAB INC. Disclosed in part 1
A-2014-00580 Information regarding DUCHOL ECT, Drug Identification Number (DIN) 00391484 by DUCHESNAY INC. Disclosed in part 2
A-2014-00587 Adverse Reaction Report (AER) for ISOFLURANE. Report number: 000562726. Disclosed in part 4
A-2014-00594 Adverse Reaction Report (AER) for HUMIRA. Report numbers: E2B_00045214, E2B_00044694, E2B_00035301, E2B_00035567. All disclosed 42
A-2014-00596 Adverse Reaction Report (AER) for HUMIRA. Report numbers: 000578131, 000563960, 000578769. Disclosed in part 11
A-2014-00608 Adverse Reaction Report (AER). Report number: 000566726. Disclosed in part 4
A-2014-00614 All correspondence with the Canadian Home Builders' Association that relates to radon. (Jan 1, 2006 to Dec 31 2007). All disclosed 3
A-2014-00625 Product Monograph for the product NOREPINEPHRINE BITARTRATE INJ 1MG/ML USP, DIN 00893285 by SANDOZ CANADA INCORPORATED. All disclosed 1
A-2014-00636 Information regarding PICO-SALAX, Drug Identification Number (DIN) 02254794 by Ferring Inc. Disclosed in part 111
A-2014-00646 All statistics or other data related to the number of Offences registered by Health Canada, concerning the labelling accuracy of ingredients contained in listings and Nutritional values in tables reported by Food Manufacturers. (Aug 29, 2008 to Aug 28, 2014). No records exist 0
A-2014-00647 All statistics or other data related to the number of inspections carried out on the listing of ingredients and tabulation of Nutritional values. (Sep 3, 2008 to Sep 2, 2014). No records exist 0
A-2014-00648 Documents regarding contracts of external consultants on the development of Health Canada's Nutrition Labelling Survey. (Jan 1, 2013 to Sep 2, 2014). No records exist 0
A-2014-00656 Adverse Reaction Report (AER). Report number: 000535796. Disclosed in part 7
A-2014-00672 All reported incidents, injuries, complaints, deaths and all other adverse events reported that involve a Daisy Powerline Model 880 air rifle. No records exist 0
A-2014-00688 Most recent inspection reports for the following health centres/hospitals in Nunavut: Baker Lake Health Centre, Chesterfield Inlet Health Centre, Baffin Regional Hospital (Iqaluit), Department of Health and Social Services (Iqaluit), Pangnirtung Health Centre, Pond Inlet Health Centre, Qikiqtarjuaq Health Centre, Rankin Inlet Health Centre and Whale Cove Health Centre. No records exist 0
A-2014-00689 Adverse Reaction Report (AER). Report number: 000595158. Disclosed in part 3